Canaccord Genuity Maintains Buy on AbbVie, Raises Price Target to $338
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice TargetHot
Canaccord Genuity analyst Gary Nachman maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $290 to $338.
Canaccord Genuity analyst Gary Nachman maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $290 to $338.